Pioneering cancer test company wants court to slow potential sale of Invitae’s cancer-monitoring products

A U.S. District Court jury said last year that Invitae owed Natera close to $20 million for infringing three patents around personalized cancer monitoring.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks